LifeArc negotiates exclusive licence deal with Nemysis for oral iron supplement technology
IHAT, a novel synthetic material, is a commercially viable alternative to ferrous salts for iron supplementation.
LifeArc, the medical research charity formerly known as MRC Technology, has negotiated a licence for an oral iron supplement technology with Nemysis. Iron oxo-hydroxide adipate tartrate (IHAT) was developed at the Medical Research Council (MRC) Human Nutrition Research Unit, whose research LifeArc supports to increase the health benefits arising from MRC research. Under the licence Nemysis will develop, manufacture and market the oral iron supplement technology.
Iron deficiency is the most common nutritional deficiency in the world. Children, pre-menopausal women and people with a poor diet such as the elderly, those in the developing world or leading busy lifestyles are most susceptible to iron deficiency and associated iron deficiency anaemia (IDA). Iron deficiency and IDA is estimated to affect 1 billion people worldwide and is one of the top-10 risk factors contributing to the global burden of disease (WHO’s top 10 list for disease cure and prevention).
Current supplements for iron deficiency include ferric compounds which are very poorly absorbed (~2%) and ferrous compounds which are associated with well-recognised toxicity issues that lead to gastrointestinal side effects, poor compliance and additional healthcare costs. IHAT is a novel synthetic material based on the chemistry of natural, digested dietary iron. Due to its low manufacturing cost, near equivalent bioavailability to ferrous salts and increased safety profile, IHAT is a commercially viable alternative to ferrous salts for iron supplementation.
Andrew Farquharson, Executive Director Technology Transfer at LifeArc, said: “There is a major unmet need for new oral iron supplements that offer reduced gastrointestinal side effects and we are delighted to have helped translate this innovative research from the MRC. IHAT is an exciting oral supplement that we hope will soon be available to patients worldwide.”
Mr Danilo Casadei Massari, Chief Executive Officer, Nemysis, said: “This is an exciting time for us all. Nemysis is a newly founded specialty pharmaceutical company that focuses on the research and development of proprietary products with unique safety profiles to address Iron Deficiency/Anaemia and Celiac Disease. We welcome the opportunity to develop up to commercial stage products based on this innovative technology.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance